Benzodiazepines Show No Increased Risk for Birth Defects
A new large-scale study finds no link between first-trimester exposure and major congenital malformations for pregnancies.
Updated on Oct. 27, 2026 in Pregnancy
Live Poll
Does new research on medication safety change how much you trust your doctor's prenatal advice?
A new study published in the Annals of Internal Medicine found no link between first-trimester benzodiazepine use and major birth defects. Researchers analyzed millions of U.S. pregnancies to reach these findings, which offer clarity for expectant parents navigating medication choices.
Why it matters
Understanding the safety of medications during pregnancy is essential for families managing existing health conditions. This large-scale analysis provides critical reassurance that common benzodiazepine use does not significantly elevate the risk of congenital malformations.
The study examined over 4.2 million pregnancies, revealing that malformation risk was nearly identical for exposed and unexposed groups. For instance, Medicaid recipients showed a 4.0% adjusted absolute risk in exposed pregnancies versus 4.1% in the nonexposed group.
The details
Researchers performed a population-based cohort study using Medicaid data from 2000 to 2018 and Merative MarketScan data from 2003 to 2020 to track birth outcomes. By comparing malformation rates between pregnancies with and without first-trimester exposure, they calculated an adjusted relative risk of 0.99. The study further confirmed that there was no dose-response relationship observed in the analyzed patient cohorts.
Timeline
2000-2018: Medicaid database data collection period.
2003-2020: Merative MarketScan database data collection period.
October 13, 2026: Publication of the study results in the Annals of Internal Medicine.
The Home Front
This research follows a growing trend of large-scale database studies intended to provide safer guidance for expectant families. It adds to a body of clinical evidence that helps patients and doctors make informed decisions about routine prenatal care and medication management.
If you are pregnant or planning to become pregnant, use these findings as a baseline for a conversation with your healthcare provider about your current prescriptions. Do not adjust any medication dosages or stop taking prescribed treatments without first consulting your doctor.
The takeaway
This large study suggests that first-trimester benzodiazepine exposure does not increase the risk of major birth defects. Always maintain an open dialogue with your obstetrician or primary care physician regarding any medications you take during pregnancy.
Further reading
Learn more about managing health during your journey in our Pregnancy section.
Source note: This article includes information reported by Neurology Advisor.
Live Poll
Does new research on medication safety change how much you trust your doctor's prenatal advice?
